Company Overview and News

28
Tracking Robert Karr's Joho Capital Portfolio - Q2 2018 Update

2018-08-20 seekingalpha - 2
The top three positions are Alibaba Group Holdings, Cognex Corporation, and Floor & Décor Holdings. They add up to ~82% of the portfolio.
BABA ALB EL HUYA CGNX HXL FND HXL SBUX FEDU

 
5 Unusual Earnings Winners

2018-07-31 247wallst
We are in the heart of this earnings reporting season, and it is not just the big stocks on the move. Some smaller and mid-cap stocks were making massive moves in Tuesday’s session.
AJRD CGNX TREX TRI ILMN KLAC

 
Cognex Corporation (CGNX) CEO Rob Willett on Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Greetings, and welcome to the Cognex Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode [Operator Instructions]. As a reminder, this conference is being recorded.
CGNX

 
CGNX / Cognex Corp. COGNEX CORPORATION 8-K (Current Report)

2018-07-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K
CGNX

 
191
Stocks To Watch: Apple, Harley And Tesla On The Marquee

2018-07-28 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
YUM CAT BNPQY ILMN PGNX SLGL RGR 1128 ZNGA MVBFP MVBFO 1928 AKAM LNG FTSI JACK LKQ RECN SPA GPRO BNPZY BABA ITW NEXT SPG UTHR FCAU MGM FB FIT CAAP FRC TM CGNX DVN MDCO ATVI SJMHY MLCO PSBQ AGN AAPL RIG BIDU STRA LUV CBS WYNN CEPU HUD AWR WYNMF BNPQF HMC 0880 EOG BHI KHC INBK CCOI CAKE WYNMY CBOE HAFC CQP TWX PXD UAL RMD PSBH FUV DOV VLKAY SMG SQ BY TTWO AAL IDXX HOG CMG BRK.A BP MSBI FRT SJMHF PFE PG STX CHE WGO CCBG COO MYL UCFC CPLA QCRH GM RMD PII DAL MSCI LFUS OSS F XPO CMCSA SCHYF P COG TRTN DWDP MFSF MVBF 506186 GLXYENT BMRC TXT TELL SCHYY

28
20 Automation Stocks for the Revolution in Robotics

2018-07-27 investorplace - 4
With automated technologies, the domain of fantasy and science-fiction is steadily becoming not only reality, it’s becoming the new norm. The robotic revolution has dramatically altered the economic landscape, driving productivity primarily in manufacturing and in many other sectors. As a result, automation stocks are virtual necessities for your portfolio.
LMT MIDD A CGNX CTRL ISRG EKSO ABB TER HON AAPL EMR OII BRKS ROK

 
Yaskawa Electric's Earnings Report Underlines The Uncertainties In Automation

2018-07-13 seekingalpha
Yaskawa's reported earnings were good, with nearly 20% revenue growth and 30% operating earnings growth on healthy demand for both motion control and robotics products.
6506 FANUY CGNX YASKY YASKF

 
CGNX / Cognex Corp. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us1924221039_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) COGNEX CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 192422103 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pag
CGNX

 
CGNX / Cognex Corp. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us1924221039_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) COGNEX CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 192422103 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pag
CGNX

19
Bulletproof Investing Performance Update: Week 32

2018-07-06 seekingalpha - 1
It's been six months since I presented 4 hedged portfolios and 10 top names in week 32 of my Marketplace service (January 4th). Here's how everything did.
ALGN SQ SPR CGNX AZO CTLR NFLX DLTR X GOOGL WWE NSP CLR BA BEAT ORLY

15
Keyence Is A Key Enabler In Factory Automation

2018-06-25 seekingalpha
Keyence is a leader in several mission-critical areas of factory automation, including machine vision and advanced sensors/measurement, and management focuses on providing unmatched capabilities.
KYCCF CGNX

15
A Buyable Dip In Cognex?

2018-06-23 seekingalpha
Cognex shares have seen a sharp correction as weak iPhone sales drive a sharp decline in 2018 machine vision orders in the consumer electronics space.
KYCCF CGNX

57
Analyzing The ROBO Global Robotics And Automation ETF

2018-06-23 seekingalpha - 1
The analysis of each ETF holding is done using free cash flow as the primary determinant of value.
HLX CGNX IRBT YASKY ISRG ZBRA NOVT 6506 VALU IPGP 6324 BRKS OII ROK MZOR YASKF

57
Analyzing The ROBO Global Robotics & Automation ETF

2018-06-22 seekingalpha - 1
The analysis of each ETF holding is done using free cash flow as the primary determinant of value.
HLX CGNX IRBT YASKY ISRG ZBRA NOVT 6506 VALU IPGP 6324 BRKS OII ROK MZOR YASKF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CGNX / Cognex Corp. on message board site Silicon Investor.

Cognex - Looks undervalued... Cognex - Looks undervalued... Cognex - Looks undervalued... CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles
Cognex (CGNX-OTC) Did you know... Cognex (CGNX-OTC) Did you know... Cognex (CGNX-OTC) Did you know...
CUSIP: 192422103